Inspire Medical Systems Reports Strong Q3 2026 Results with Robust Growth and Favorable Coding Outlook
On November 2, 2026, Inspire Medical Systems reported its third-quarter financial results for the year, delivering revenue and adjusted operating income slightly ahead of expectations. The company's chairman and CEO, Tim Herbert, highlighted the strong quarter in a conference call with investors, emphasizing the focus on patient outcomes and better treatment leading to better sleep and health.
Herbert noted that obstructive sleep apnea (OSA), a largely untreated condition, has far-reaching impacts beyond just sleep quality, affecting patients' overall health. With Inspire's hypoglossal nerve stimulation therapy being the market leader for treating OSA, Herbert expressed confidence in the company's approach and results.
One of the key highlights from the quarter was the sequential revenue increase of 3%, a testament to the company's growth momentum. Operating cash flow also remained strong, underscoring Inspire Medical Systems' financial stability.
In terms of coding, which has been a major focus for the industry in recent times, Herbert provided an update on the progress made by the company and its partners. The new billing procedures implemented earlier this year required some time for implanting sites to get accustomed to, but centers have now gained experience with a stable framework.
Herbert also discussed the impact of the recently proposed OPPS rules for 2027 hospital and ASC reimbursement, noting that while the final rule has not yet been released, it could lead to significant increases in reimbursement rates. Moreover, he highlighted the approval of a dedicated Category I CPT code for single-lead hypoglossal nerve stimulation, set to take effect on January 1, 2028.
This development is expected to simplify coding and reimbursement processes, thereby expanding access to Inspire therapy. The company will continue to provide updates as the RUC valuation and reimbursement review process progresses toward the code's effective date.
Herbert also emphasized the importance of clinical evidence in supporting Inspire therapy's efficacy and positive impact on patient outcomes. Recent studies and publications further validate the benefits of Inspire treatment, including a full results report from the Inspire V trial, secondary analysis of STAR trial data, a TriNetX meta-analysis, and the PREDICTOR study.
In conclusion, Inspire Medical Systems' Q3 2026 results demonstrate robust growth, with a favorable coding outlook bolstering investor confidence. As the company continues to drive innovation in treating obstructive sleep apnea, its commitment to delivering better patient outcomes remains unwavering.
